Abstrakt

The pulmonary arterial pressure has a large impact on patients with chronic lung disease and decides on prognosis and exacerbation rate. The underlying mechanisms are not completely understood. Targeted therapy is indicated for group 1 (PAH) patients with concomitant lung disease and group 3 PH with severe PH (severe PH-lung). The criteria for these entities should be checked in expert centers for both PH and lung disease and strictly followed. Future randomized controlled studies with PAH drugs should selectively include patients who meet the criteria for severe PH-lung to give these drugs a fair chance for a positive outcome.

Autoreninformation

Autoren

• H. Olschewski

Abteilungen

• Klinische Abteilung für Lungenkrankheiten, Universitätsklinik für Innere Medizin, Graz, Österreich

Adresse

Univ.Prof. Dr. Horst Olschewski
Klinische Abteilung für Lungenkrankheiten
Universitätsklinik für Innere Medizin
Auenbruggerplatz 20
8036 Graz, Österreich
Email: [email protected]

Citation